GLENMARK PHARMACEUTICALS Q3 FY25 Results
GLENMARK PHARMACEUTICALS has released its financial results for the Q3 quarter of Financial Year 24-2025. Here's a comprehensive breakdown of the company's performance:
Revenue Analysis
- Current Quarter Revenue: Rs. 3,387.55 Cr
- Quarter-on-Quarter (QoQ) Change: -1.35% (Previous Quarter: Rs. 3,433.80 Cr )
- Year-on-Year (YoY) Change: 35.14% (Same Quarter Last Year: Rs. 2,506.70 Cr )
Profitability Metrics
- Net Profit: Rs. 348.03 Cr
- QoQ Profit Change: -1.82% (Previous Quarter: Rs. 354.49 Cr )
- YoY Profit Change: -205.20% (Same Quarter Last Year: Rs. -330.82 Cr )
Shareholder Returns
- Earnings Per Share (EPS): Rs. 12.33
- QoQ EPS Change: -1.75% (Previous Quarter: Rs. 12.55)
- YoY EPS Change: -199.04% (Same Quarter Last Year: Rs. -12.45)
Performance Summary
Mixed
GLENMARK PHARMACEUTICALS had a complex financial situation. Different parts of the business are performing differently, showing a changing market.
This analysis provides a snapshot of GLENMARK PHARMACEUTICALS's financial performance. Investors and analysts should consider these results in the context of broader market trends and the company's long-term strategy.
Disclaimer:
This information is for informational purposes only. Please reverify all details from official sources before making any financial decisions. The accuracy and completeness of this data cannot be guaranteed.